Drug Profile
Research programme: Monoclonal antibody biosimilars - Ipca Laboratories/Outlook Therapeutics
Latest Information Update: 05 Dec 2018
Price :
$50
*
At a glance
- Originator Ipca Laboratories; Oncobiologics
- Developer Ipca Laboratories; Outlook Therapeutics
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer; Immunological disorders
Most Recent Events
- 03 Dec 2018 Oncobiologics is now called Outlook Therapeutics
- 28 Jul 2018 No recent reports of development identified for research development in Cancer in India
- 28 Jul 2018 No recent reports of development identified for research development in Cancer in USA